ClinicalTrials.gg
RecruitingNCT05999877PICAROSUpdated Nov 4, 2026

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

An observational study in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Recruiting at 50 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
315
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.

Planned enrollment
4th of 12
315 · median 136
Started
2023
with 3 others
Observational
12 of 42
3 open now
Primary completion
2029-03
later than 16 of 20 live
Registered
34th of 42
by date

Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2023, is one of 12 observational ones, reaches primary completion later than 16 of the 20 other live ones, and was the 34th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

Read the detailed description

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Observational
  • Chronic lymphocytic leukemia
  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • (for alive patients).

Exclusion criteria

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
315 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

  • Cohort 2

    Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

    Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1). In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors: 1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression), 2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV). 3. cardiovascular comorbidities (yes/no).

    Time frame: 24 months after treatment initiation (cohort 1).

  2. Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)

    rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

    Time frame: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

Secondary outcomes

  1. Acalabrutinib±venetoclax doses (cohorts 1 and 2).

    Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

    Time frame: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

  2. Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).

    Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

    Time frame: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

  3. Treatment duration in months (cohorts 1 and 2).

    Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles. Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

    Time frame: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

  4. Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).

    Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1). The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time: PDC (%)=(No.days covered)/(No.days of interest)×100

    Time frame: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

  5. TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).

    TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause \[i.e. deaths are not censored\]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

    Time frame: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

  6. OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).

    OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

    Time frame: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

  7. Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).

    Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation. Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available). Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available). They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

    Time frame: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

07

Study locations

15 of 50 sites recruiting
  • Research Site
    Almería, Andalusia 4009, Spain
    Recruiting
  • Research Site
    Córdoba, Andalusia 14004, Spain
    Recruiting
  • Research Site
    Granada, Andalusia 18014, Spain
    Recruiting
  • Research Site
    Jaén, Andalusia 23007, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Marbella, Andalusia 29603, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Málaga, Andalusia 29010, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Seville, Andalusia 41013, Spain
    Recruiting
  • Research Site
    Zaragoza, Aragon 50009, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Zaragoza, Aragon 50009, Spain
    Recruiting
  • Research Site
    Palma de Mallorca, Balearic Islands 7010, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Palma de Mallorca, Balearic Islands 7198, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Donostia / San Sebastian, Basque Country 20014, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Galdakao, Basque Country 48960, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Las Palmas de Gran Canaria, Canary Islands 35016, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Las Palmas de Gran Canaria, Canary Islands 35019, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    San Cristóbal de La Laguna, Canary Islands 38320, Spain
    Recruiting
  • Research Site
    Santander, Cantabria 39008, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Salamanca, Castille and León 37007, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Segovia, Castille and León 40002, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Valladolid, Castille and León 47003, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Valladolid, Castille and León 47012, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Guadalajara, Castille-La Mancha 19002, Spain
    Recruiting
  • Research Site
    Toledo, Castille-La Mancha 45004, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, Catalonia 8003, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, Catalonia 8025, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, Catalonia 8035, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Barcelona, Catalonia 8036, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Granollers, Catalonia 8402, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    L'Hospitalet de Llobregat, Catalonia 8908, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Lleida, Catalonia 25198, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Terrassa, Catalonia 8221, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Ourense, Galicia 32005, Spain
    Recruiting
  • Research Site
    Santiago de Compostela, Galicia 15706, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Vigo, Galicia 36312, Spain
    Recruiting
  • Research Site
    Madrid, Madrid 28006, Spain
    Recruiting
  • Research Site
    Madrid, Madrid 28031, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Madrid, Madrid 28034, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Madrid, Madrid 28040, Spain
    Recruiting
  • Research Site
    Madrid, Madrid 28041, Spain
    Recruiting
  • Research Site
    Madrid, Madrid 28046, Spain
    Recruiting
  • Research Site
    Madrid, Madrid 28905, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Madrid, Madrid 28911, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Majadahonda, Madrid 28222, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    El Palmar, Murcia 30120, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Murcia, Murcia 30008, Spain
    Recruiting
  • Research Site
    Oviedo, Principality of Asturias 33011, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Alicante, Valencia 3010, Spain
    Recruiting
  • Research Site
    Valencia, Valencia 46010, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Valencia, Valencia 46014, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Valencia, Valencia 46026, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2029, 68 months after the start.

Of 34 industry-sponsored observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 66. This study's planned 68 months is above that.

Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Aug 21, 2023
StartActual
Jul 11, 2023
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Sep 28, 2026
Sites
3 sites added. 32 sites changed recruiting status (21 now active, not recruiting, 11 now recruiting)
Show 32 sites
  • Research Site · Almería, Spainno status→Recruiting
  • Research Site · Córdoba, Spainno status→Recruiting
  • Research Site · Granada, Spainno status→Recruiting
  • Research Site · Jaén, Spainno status→Active, not recruiting
  • Research Site · Marbella, Spainno status→Active, not recruiting
  • Research Site · Málaga, Spainno status→Active, not recruiting
  • Research Site · Seville, Spainno status→Recruiting
  • Research Site · Zaragoza, Spainno status→Active, not recruiting
  • Research Site · Palma de Mallorca, Spainno status→Active, not recruiting
  • Research Site · Las Palmas de Gran Canaria, Spainno status→Active, not recruiting
  • Research Site · San Cristóbal de La Laguna, Spainno status→Recruiting
  • Research Site · Santander, Spainno status→Active, not recruiting
  • Research Site · Salamanca, Spainno status→Active, not recruiting
  • Research Site · Segovia, Spainno status→Active, not recruiting
  • Research Site · Valladolid, Spainno status→Active, not recruiting
  • Research Site · Guadalajara, Spainno status→Recruiting
  • Research Site · Toledo, Spainno status→Active, not recruiting
  • Research Site · Barcelona, Spainno status→Active, not recruiting
  • Research Site · Granollers, Spainno status→Active, not recruiting
  • Research Site · L'Hospitalet de Llobregat, Spainno status→Active, not recruiting
  • Research Site · Lleida, Spainno status→Active, not recruiting
  • Research Site · Terrassa, Spainno status→Active, not recruiting
  • Research Site · Ourense, Spainno status→Recruiting
  • Research Site · Santiago de Compostela, Spainno status→Active, not recruiting
  • Research Site · Vigo, Spainno status→Recruiting
  • Research Site · Madrid, Spainno status→Recruiting
  • Research Site · Majadahonda, Spainno status→Active, not recruiting
  • Research Site · El Palmar, Spainno status→Active, not recruiting
  • Research Site · Murcia, Spainno status→Recruiting
  • Research Site · Oviedo, Spainno status→Active, not recruiting
  • …and 2 more on the registry record
Show 3 added (3 Spain)
  • Research Site · Donostia / San Sebastian, Spain
  • Research Site · Galdakao, Spain
  • Research Site · Zaragoza, Spain
across 2 updates, Sep 28, 2026 – Nov 4, 2026
Enrollment
192 (actual)→315 (estimated)
Sep 28, 2026
Contact
Study contact now listed: added i•••@astrazeneca.com · •••9479. See the current contact
Sep 28, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added. 8 sites changed recruiting status (7 now recruiting, 1 now active, not recruiting)
    Show 8 sites
    • Research Site · Almería, SpainActive, not recruiting→Recruiting
    • Research Site · Las Palmas de Gran Canaria, SpainRecruiting→Active, not recruiting
    • Research Site · San Cristóbal de La Laguna, SpainActive, not recruiting→Recruiting
    • Research Site · Guadalajara, SpainActive, not recruiting→Recruiting
    • Research Site · Madrid, SpainActive, not recruiting→Recruiting
    • Research Site · Madrid, SpainActive, not recruiting→Recruiting
    • Research Site · Madrid, SpainActive, not recruiting→Recruiting
    • Research Site · Alicante, SpainActive, not recruiting→Recruiting
    Show site
    • Research Site · Zaragoza, Spain
    + 1 other change: verification date
  2. Sep 28, 2026
    Active, not recruiting→Recruiting
    2 sites added. 47 sites changed recruiting status (39 now active, not recruiting, 8 now recruiting)
    Show 47 sites
    • Research Site · Almería, Spainno status→Active, not recruiting
    • Research Site · Córdoba, Spainno status→Recruiting
    • Research Site · Granada, Spainno status→Recruiting
    • Research Site · Jaén, Spainno status→Active, not recruiting
    • Research Site · Marbella, Spainno status→Active, not recruiting
    • Research Site · Málaga, Spainno status→Active, not recruiting
    • Research Site · Seville, Spainno status→Recruiting
    • Research Site · Zaragoza, Spainno status→Active, not recruiting
    • Research Site · Palma de Mallorca, Spainno status→Active, not recruiting
    • Research Site · Palma de Mallorca, Spainno status→Active, not recruiting
    • Research Site · Las Palmas de Gran Canaria, Spainno status→Active, not recruiting
    • Research Site · Las Palmas de Gran Canaria, Spainno status→Recruiting
    • Research Site · San Cristóbal de La Laguna, Spainno status→Active, not recruiting
    • Research Site · Santander, Spainno status→Active, not recruiting
    • Research Site · Salamanca, Spainno status→Active, not recruiting
    • Research Site · Segovia, Spainno status→Active, not recruiting
    • Research Site · Valladolid, Spainno status→Active, not recruiting
    • Research Site · Valladolid, Spainno status→Active, not recruiting
    • Research Site · Guadalajara, Spainno status→Active, not recruiting
    • Research Site · Toledo, Spainno status→Active, not recruiting
    • Research Site · Barcelona, Spainno status→Active, not recruiting
    • Research Site · Barcelona, Spainno status→Active, not recruiting
    • Research Site · Barcelona, Spainno status→Active, not recruiting
    • Research Site · Barcelona, Spainno status→Active, not recruiting
    • Research Site · Granollers, Spainno status→Active, not recruiting
    • Research Site · L'Hospitalet de Llobregat, Spainno status→Active, not recruiting
    • Research Site · Lleida, Spainno status→Active, not recruiting
    • Research Site · Terrassa, Spainno status→Active, not recruiting
    • Research Site · Ourense, Spainno status→Recruiting
    • Research Site · Santiago de Compostela, Spainno status→Active, not recruiting
    • …and 17 more on the registry record
    Show 2 added (2 Spain)
    • Research Site · Donostia / San Sebastian, Spain
    • Research Site · Galdakao, Spain
    Enrollment 192 (actual)→315 (estimated)
    Contact Study contact now listed: added i•••@astrazeneca.com · •••9479. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05999877
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jul 11, 2023
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion